key: cord-0840667-kz4hded6 authors: Aslam, Saima; Danziger-Isakov, Lara; Mehra, Mandeep R title: COVID-19 Vaccination Immune Paresis in Heart and Lung Transplantation date: 2021-05-13 journal: J Heart Lung Transplant DOI: 10.1016/j.healun.2021.04.018 sha: 812507d78be55c0822b069fad67c7be746909a24 doc_id: 840667 cord_uid: kz4hded6 nan antimetabolites (such as mycophenolic acid) were associated with this poor early response. Other studies in kidney transplantation have also confirmed a sub-optimal antibody response. (9) (10) (11) (12) One study assessed T-cell responses and noted that most transplanted patients mounted spikespecific T helper cell responses, albeit in significantly reduced frequency compared to controls and dialysis patients. (11) Two separate studies in the Journal in heart (Peled et al) SARS-CoV-2 specific T-cells noted in 4/12 (33.3%) 9 weeks after Dose 2. Mycophenolate use associated with lack of IgG in univariate analysis. SOT is solid organ transplant, KT is kidney transplant, HT is heart transplant, LT is lung transplant *Antibody testing for SARS-CoV-2 anti-spike IgG was performed by the following tests: Boyarsky et al -anti-SARS-CoV-2 Spike S1 IgG ELISA (Euroimmun, Lubeck, Germany). Some samples tested using the SARS-CoV-2 S enzyme immunoassay (Roche Elecsys) that tests for antibodies against the receptor-binding domain of the SARS-CoV-2 spike protein. Yi et alnot mentioned in paper Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Developing Covid-19 Vaccines at Pandemic Speed Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review SARS-CoV-2 Vaccination in Heart and Lung Transplantation: Recommendations from the ISHLT COVID-19 Task Force An early experience on the effect of solid organ transplant status on hospitalized COVID-19 patients Immunogenicity of a Single Dose of SARS-CoV Messenger RNA Vaccine in Solid Organ Transplant Recipients Kidney Transplant Recipients Rarely Show an Early Antibody Response Following the First COVID-19 Vaccine Administration Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients Impaired Humoral and Cellular Immunity after SARS-CoV2 BNT162b2 (Tozinameran) Prime-Boost Vaccination in Kidney Transplant Recipients Reduced humoral response to mRNA SARS-Cov-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus BNT162b2 vaccination in heart transplant recipients: clinical experience and antibody response Immunogenicity of BNT162b2 mRNA COVID Vaccine and SARS-CoV-2 Infection in Lung Transplant Recipients Serologic vaccination response after solid organ transplantation: a systematic review Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect Comparison of the Clinical Performances of the Abbott Alinity IgG, Abbott Architect IgM, and Roche Elecsys Total SARS-CoV-2 Antibody Assays Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles among hospitalized patients in two US cities COVID-19 infection in Solid Organ Transplant Recipients after SARS-CoV-2 vaccination Randomized, double-blind comparison of standard-dose vs. high-dose trivalent inactivated influenza vaccine in pediatric solid organ transplant patients A Double-Blind, Randomized Trial of High Dose vs Standard-Dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients Two Doses of Inactivated Influenza Vaccine Improve Immune Response in Solid Organ Transplant Recipients: Results of TRANSGRIPE 1-2, a Randomized Controlled Clinical Trial Regeneron Pharmaceuticals Inc. Regeneron reports positive interim data with REGEN-COV™ antibody cocktail used as passive vaccine to prevent COVID-19 Eli Lilly and Company. Lilly's neutralizing antibody bamlanivimab COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents Grupper et al -LIAISON SARS-CoV-2 S1/S2 IgG chemiluminescent assay (DiaSorin S.p.A., Saluggia, Italy) used to detect IgG antibodies directed against a recombinant S protein (S1/S2). Titers 15 AU/mL considered positive IgG against the trimeric spike S1 protein (Diasorin, Saluggia, Italy)